Logo

MiNK Therapeutics, Inc.

INKT

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is… read more

Healthcare

Biotechnology

4 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$11.25

Price

+0.85%

$0.10

Market Cap

$52.786m

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financial Reports

Key metrics over the past few years and other important metrics. Amounts in USD.

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$0.00

-

1y CAGR

-

3y CAGR

-

5y CAGR
Earnings

-$12.356m

-14.6%

1y CAGR

+19.1%

3y CAGR

+16.1%

5y CAGR
EPS

-$3.06

-9.3%

1y CAGR

+23.1%

3y CAGR

+19.3%

5y CAGR
Book Value

-$13.513m

$14.964m

Assets

$28.477m

Liabilities

$5.725m

Debt
Debt to Assets

38.3%

-0.5x

Debt to EBITDA
Free Cash Flow

-$1.345b

-13976.9%

1y CAGR

-4640.0%

3y CAGR

-3491.6%

5y CAGR
No items found.
Press Releases
Statements and updates from the company
↑ TopSummaryPriceFinancialsPress Releases